Johnson & Johnson stock (US4781601046): pharma and consumer giant after latest earnings and Kenvue stake sale

Johnson & Johnson has reported strong quarterly figures and is simplifying its portfolio after spinning off Kenvue. Investors are watching the pharma pipeline, MedTech momentum and the impact of recent divestments on future growth and cash flows.

Johnson & Johnson has remained in the spotlight following the release of its latest quarterly results and ongoing portfolio moves after the Kenvue spin-off. The healthcare group reported growth in its pharmaceutical and MedTech businesses and updated its full-year guidance, according to a quarterly report published in April 2026 on the company’s website and coverage by Reuters as of 04/18/2026.

The company also continues to manage its remaining stake in Kenvue, the consumer health business it spun off in 2023, a transaction that reshaped its profile toward higher-margin prescription drugs and medical devices, as highlighted by Johnson & Johnson as of 08/23/2023. Investors in the United States and Europe are now focusing on earnings momentum, legal risks and capital allocation after these changes.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare, pharmaceuticals, medical devices
• Headquarters/country: New Brunswick, New Jersey, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Prescription medicines, MedTech products, surgical and orthopedic devices
• Home exchange/listing venue: New York Stock Exchange (ticker: JNJ)
• Trading currency: US dollar (USD)

Johnson & Johnson: core business model

Johnson & Johnson is a diversified healthcare group focusing on pharmaceuticals and medical technology. After the separation of its consumer health division into Kenvue, the company derives most of its revenue and profit from innovative prescription medicines and a broad portfolio of medical devices, according to an annual report published in February 2024 on its investor relations page and noted by Johnson & Johnson as of 02/16/2024.

The pharmaceutical division develops treatments in areas such as oncology, immunology, neuroscience, cardiovascular disease and pulmonary hypertension. This business typically generates higher margins than traditional consumer health products and is driven by patent-protected medicines and a large pipeline of clinical-stage assets, as described in the 2024 Form 10-K filed with the SEC and summarized by SEC filings as of 02/16/2024.

The MedTech segment provides a wide range of products used in surgery, orthopedics, vision care and interventional solutions. These devices are used by hospitals and clinics around the world and give Johnson & Johnson broad exposure to procedure volumes and demographics, with aging populations and rising healthcare access supporting underlying demand, as detailed in the company’s 2024 annual report and referenced by Johnson & Johnson as of 02/16/2024.

Main revenue and product drivers for Johnson & Johnson

In its 2024 annual report, Johnson & Johnson reported full-year 2023 sales of around $85 billion for its continuing operations after the Kenvue separation, with pharmaceuticals and MedTech as the primary contributors, according to Johnson & Johnson as of 02/16/2024. The pharmaceutical unit generated the majority of operating profit, while MedTech benefited from the recovery of elective procedures after the pandemic.

Key medicines driving revenue include oncology and immunology therapies, although individual product names and exact contributions vary over time as new indications are approved and older medicines face competition. The company has emphasized that future growth depends on successfully launching late-stage pipeline assets and expanding existing products into new treatment settings, as outlined during an investor presentation in December 2024 and reported by Reuters as of 12/05/2024.

MedTech revenue is supported by orthopedic implants, surgical technologies and cardiovascular devices. Johnson & Johnson has highlighted robotics, digital surgery and minimally invasive procedures as areas where it is investing heavily to defend and grow its market share, according to comments made at a capital markets day in 2024 and covered by Bloomberg as of 11/15/2024. For US investors, this means exposure to procedure growth in American hospitals as well as international markets.

Recent earnings and guidance signals

In April 2026, Johnson & Johnson released quarterly results that showed continued growth in both pharmaceuticals and MedTech. The company reported higher revenue and adjusted earnings per share compared with the prior-year period and reaffirmed or slightly raised its full-year 2026 guidance, according to a press release on its website and a news report from Reuters as of 04/18/2026. Detailed figures highlighted steady performance despite pricing pressures and generic competition in some product categories.

The company pointed to strong demand for key oncology and immunology treatments as well as solid growth in its surgical and interventional solutions franchises. Management also noted that currency effects and portfolio changes, including the fully separated consumer health business, affected year-on-year comparisons, as described in the April 2026 earnings materials cited by Johnson & Johnson as of 04/18/2026.

For US investors, the earnings update provided further insight into how the company balances investments in research and development with shareholder returns through dividends and share repurchases. Johnson & Johnson has a long history of paying and increasing dividends, and it reiterated its focus on maintaining a strong balance sheet and investment-grade credit profile during the April 2026 conference call, as reported by Bloomberg as of 04/18/2026.

Portfolio reshaping and Kenvue spin-off

One of the most significant recent strategic moves for Johnson & Johnson was the spin-off of its consumer health business into Kenvue, completed in 2023. The transaction created a separate publicly traded company focused on over-the-counter medicines and personal care products, while Johnson & Johnson retained a substantial stake that it has been gradually reducing, according to company announcements and coverage from Reuters as of 08/23/2023.

By focusing on pharmaceuticals and MedTech, Johnson & Johnson aims to concentrate on faster-growing, higher-margin segments of healthcare. The company has indicated that this profile should support increased investment in innovative therapies and devices, while potential proceeds from Kenvue stake sales can be used for debt reduction, research and development, or returns to shareholders, as described in an investor presentation following the spin-off and summarized by Johnson & Johnson as of 08/23/2023.

For investors, the spin-off changed the risk and return profile of Johnson & Johnson. The group is now less exposed to consumer spending on over-the-counter products but more tied to clinical and regulatory outcomes in pharmaceuticals and medical devices. This shift makes pipeline progress, regulatory approvals and competition from other large healthcare firms even more important to monitor.

Legal risks and litigation environment

Johnson & Johnson continues to face litigation related to historical products, including talc-based items and certain medical devices. The company has tried multiple approaches to manage these liabilities, including proposed settlements and restructuring steps, some of which have been challenged or rejected in US courts, as reported by AP News as of 04/30/2024.

In 2024, Johnson & Johnson announced a proposed multi-billion-dollar settlement framework intended to address a large portion of talc-related claims, while continuing to state that its products are safe. The discussions and court decisions around these proposals have influenced investor sentiment and remain a key overhang when valuing the stock, according to legal coverage and analysis in the US business press summarized by Reuters as of 05/01/2024.

For US and international shareholders, this legal backdrop adds uncertainty to long-term cash flow forecasts. While Johnson & Johnson maintains a strong balance sheet and high cash generation, the final cost and timing of any large settlements could affect funds available for acquisitions, research projects or shareholder distributions in future years.

Why Johnson & Johnson matters for US investors

Johnson & Johnson is one of the largest healthcare companies on the New York Stock Exchange and forms a significant component of major US equity indices. As a result, its earnings and guidance can influence sentiment across the broader healthcare sector and even the overall US market, according to index composition data from S&P Dow Jones Indices cited by S&P Global as of 01/10/2025.

The company’s pharmaceuticals and MedTech businesses give investors indirect exposure to demographic trends in the United States, such as an aging population and rising prevalence of chronic diseases. At the same time, Johnson & Johnson’s global footprint means that US investors are also participating in healthcare demand growth in Europe, Asia and emerging markets, as highlighted in its 2024 annual report referenced by Johnson & Johnson as of 02/16/2024.

For income-oriented investors, the stock’s dividend track record is a focal point, while more growth-focused investors often concentrate on the research pipeline and MedTech innovation. Because of this combination, Johnson & Johnson is frequently discussed as a core holding in US healthcare portfolios, though each investor must weigh the benefits and risks in light of personal objectives and risk tolerance.

Conclusion

Johnson & Johnson is transitioning into a more focused pharmaceuticals and MedTech company after the Kenvue spin-off and continues to report solid earnings, supported by key medicines and medical devices. At the same time, litigation over historical products and competition in major therapeutic areas add uncertainty to long-term forecasts. For US investors, the stock offers exposure to global healthcare demand and a long-standing dividend, but the evolving legal and regulatory landscape means that careful monitoring of new developments and company disclosures remains important.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.